Inactivation of the tumor suppressor p53 and/or overexpression of the oncogene MDM2
frequently occur in human cancers, and are associated with poor prognosis, advanced forms …

This is a sequel to the previous Perspective “The CH–π hydrogen bond in chemistry.
Conformation, supramolecules, optical resolution and interactions involving carbohydrates” …

Abstract Taste receptor T1R1-T1R3 can be activated by binding to several natural ligands,
eg, l-glutamate and 5′-ribonucleotides etc., thereby stimulating the umami taste. The …

As a tumor suppressor protein, p53 plays a crucial role in the cell cycle and in cancer
prevention. Almost 50 percent of all human malignant tumors are closely related to a …

In the vast majority of malignancies, the p53 tumor suppressor pathway is compromised. In
some cancer cells, high levels of MDM2 polyubiquitinate p53 and mark it for destruction …

Molecular dynamics (MD) simulations followed by principal component analysis were
performed to study the conformational change of MDM2 induced by p53 and two inhibitor …

Protein tyrosine phosphatase 1B (PTP1B) is a key negative regulator of insulin and leptin
signaling, which suggests that it is an attractive therapeutic target in type II diabetes and …

Binding abilities of current inhibitors to MDMX are weaker than to MDM2. Polarizable
molecular dynamics simulations (MD) followed by Quantum mechanics/molecular …

The second‐generation antiandrogen enzalutamide, targeting androgen receptor (AR), was
approved to treat castration resistant prostate cancer (CRPC) in 2012. Its resistance was …

At present, disrupting p53-MDM2 interactions through small molecule ligands is a promising
approach to safe treatment and management of human cancer. Tumor cells unlike the …